Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Agomab reported a cash position of €252.0 million as of June 30, 2026, which is expected to fund operations into the first half of 2029, bolstered by $208 million in gross proceeds from its February IPO. The company announced alignment with the FDA on the design of the NOV-ERA Phase 2b study for ontunisertib in Fibrostenosing Crohn’s Disease, establishing endoscopic passability as the primary endpoint, and expects to dose the first participants in the second half of 2026.
Key figures
- Guidance
- Confirmed 2026 outlook; initiation of NOV-ERA Phase 2b study and AGMB-447 Phase 2 study expected in second half of 2026.
- Net loss eur
- €31.0 million
- Ga expenses eur
- €12.2 million
- Rd expenses eur
- €23.0 million
- Ipo proceeds usd
- $208 million
- Cash position eur
- €252.0 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.